Understanding and overcoming metformin gastrointestinal intolerance.

@article{Bonnet2017UnderstandingAO,
  title={Understanding and overcoming metformin gastrointestinal intolerance.},
  author={Fabrice Bonnet and Andr{\'e} Scheen},
  journal={Diabetes, obesity & metabolism},
  year={2017},
  volume={19 4},
  pages={473-481}
}
Metformin is the most widely prescribed drug for patients with type 2 diabetes mellitus and the first-line pharmacological option as supported by multiple international guidelines, yet a rather large proportion of patients cannot tolerate metformin in adequate amounts because of its associated gastrointestinal (GI) adverse events (AEs). GI AEs typically encountered with metformin therapy include diarrhoea, nausea, flatulence, indigestion, vomiting and abdominal discomfort, with diarrhoea and… CONTINUE READING
Related Discussions
This paper has been referenced on Twitter 11 times. VIEW TWEETS